- The stock price of Esperion Therapeutics Inc (NASDAQ: ESPR) increased by 13.54% today. This is why.
The stock price of Esperion Therapeutics Inc (NASDAQ: ESPR) increased by 13.54% today. Investors responded positively to the company’s fourth-quarter results.
Esperion Therapeutics reported a Q4 EPS of ($1.77), which was $0.50 better than analyst estimates of ($2.27). And the revenue for the quarter was $15.4 million compared to the consensus estimate of $14.48 million.
In terms of the guidance, the company expects research and development expenses for the full year 2022 are expected to be $100 million to $110 million. And the Selling, General, and Administrative expenses for the full year 2022 are expected to be $120 million to $130 million.
And Esperion expects full-year 2022 operating expenses to be about $220 million to $240 million, inclusive of $25 million of non-cash, stock-based compensation expenses.
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.